Hemoglobin A_1c levels and 1-year mortality in patients with ST-elevation myocardial infarction undergoing...

Area of Science:

• Cardiology
• Endocrinology
• Clinical Medicine

Background:

• Diabetes mellitus is a significant risk factor for cardiovascular disease.
• Percutaneous coronary intervention (PCI) is a common procedure for treating coronary artery disease.
• Glycemic control, measured by hemoglobin A1c (HbA1c), plays a crucial role in diabetic patient outcomes.

Purpose of the Study:

• To investigate the association between different hemoglobin A1c (HbA1c) levels and short-term and 1-year mortality rates.
• To evaluate HbA1c as a predictor of clinical events in diabetic patients undergoing PCI.
• To compare mortality and hospitalization outcomes across varying glycemic control strata.

Main Methods:

• A cohort of 165 diabetic patients undergoing PCI was analyzed.
• Patients were stratified into three groups based on HbA1c levels: ≤5.6%, 5.7-6.4%, and ≥6.5%.
• In-hospital, 1-month, and 1-year mortality rates, along with hospitalization duration, were compared between groups.

Main Results:

• Patients with HbA1c ≥6.5% had significantly longer hospitalization durations (7.65 days) compared to those with normal HbA1c (4.94 days).
• In-hospital mortality was significantly higher in the highest HbA1c groups (≥6.5% and 5.7-6.4%) compared to the normal group (0%).
• Elevated HbA1c levels correlated with increased risk of adverse clinical events post-PCI.

Conclusions:

• Hemoglobin A1c levels are a reliable predictor of short-term clinical events in diabetic patients.
• Optimal glycemic control, indicated by lower HbA1c, is associated with better outcomes after PCI.
• HbA1c monitoring is essential for risk stratification and management of diabetic patients undergoing PCI.